FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to antibodies which bind to GPRC5D, and methods of using them for treating a tumor.
EFFECT: invention provides effective treatment of tumor mediated by GPRC5D.
56 cl, 14 dwg, 36 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT RECEPTOR BOUND TO G-PROTEINS, AND THEIR APPLICATION | 2015 |
|
RU2762359C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
| ANTI-VEGF-ANTIBODY AND ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION, DIAGNOSTICS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE | 2014 |
|
RU2644245C2 |
| ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
